丁丙诺啡与抗逆转录病毒药物的相互作用：核苷（酸）逆转录酶抑制剂（NRTI）地达诺辛、拉米夫定和替诺福韦。
Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.
机构信息
Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA.
出版信息
Am J Addict. 2010 Jan-Feb;19(1):17-29. doi: 10.1111/j.1521-0391.2009.00004.x.
Abstract
To improve outcomes among injection drug users with HIV and/or chronic hepatitis B, it is important to identify drug interactions between antiretroviral and opiate therapies. We report the results of a study designed to examine the interaction between buprenorphine and the nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine (ddI), lamivudine (3TC), and tenofovir (TDF). Opioid-dependent, buprenorphine/naloxone-maintained, HIV-negative volunteers (n = 27) participated in two 24-hour sessions to determine (1) pharmacokinetics of buprenorphine alone and (2) pharmacokinetics of both buprenorphine and either ddI, 3TC, or TDF. Among buprenorphine/naloxone-maintained study participants, no significant changes in buprenorphine pharmacokinetics were observed following ddI, 3TC, or TDF administration. Buprenorphine had no significant effect on NRTI concentrations. Concomitant use of buprenorphine with ddI, 3TC, or TDF results in neither a significant pharmacokinetic nor pharmacodynamic interaction.
摘要
为了改善感染 HIV 和/或慢性乙型肝炎的注射吸毒者的治疗效果，识别抗逆转录病毒和阿片类药物治疗之间的药物相互作用非常重要。我们报告了一项旨在研究丁丙诺啡与核苷（酸）逆转录酶抑制剂（NRTI）地达诺辛（ddI）、拉米夫定（3TC）和替诺福韦（TDF）之间相互作用的研究结果。接受丁丙诺啡/纳洛酮维持治疗、HIV 阴性的阿片类药物依赖志愿者（n=27）参与了两个 24 小时的疗程，以确定：（1）丁丙诺啡单独的药代动力学；（2）丁丙诺啡和 ddI、3TC 或 TDF 联合应用的药代动力学。在丁丙诺啡/纳洛酮维持治疗的研究参与者中，ddI、3TC 或 TDF 给药后丁丙诺啡的药代动力学没有明显变化。丁丙诺啡对 NRTI 浓度没有显著影响。丁丙诺啡与 ddI、3TC 或 TDF 同时使用既不会产生明显的药代动力学相互作用，也不会产生药效学相互作用。
相似文献
1
Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.
Am J Addict. 2010 Jan-Feb;19(1):17-29. doi: 10.1111/j.1521-0391.2009.00004.x.
2
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Antimicrob Agents Chemother. 2009 May;53(5):1937-43. doi: 10.1128/AAC.01064-08. Epub 2009 Mar 9.
3
[Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].
Enferm Infecc Microbiol Clin. 2006 Aug-Sep;24(7):426-30. doi: 10.1157/13091779.
4
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):406-11. doi: 10.1097/01.qai.0000167155.44980.e8.
5
Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Antimicrob Agents Chemother. 2011 Apr;55(4):1549-55. doi: 10.1128/AAC.00910-10. Epub 2011 Jan 31.
6
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
J Clin Virol. 2006 Jun;36(2):95-9. doi: 10.1016/j.jcv.2006.02.002. Epub 2006 Mar 23.
7
Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
Curr Med Chem. 2006;13(23):2789-93. doi: 10.2174/092986706778521931.
8
Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.
J Clin Pharmacol. 2005 Dec;45(12):1360-7. doi: 10.1177/0091270005281351.
9
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
AIDS. 2004 Feb 20;18(3):459-63. doi: 10.1097/00002030-200402200-00012.
10
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
AIDS. 2005 Jul 22;19(11):1183-8. doi: 10.1097/01.aids.0000176218.40861.14.
引用本文的文献
1
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Drug Alcohol Depend. 2022 Dec 1;241:109696. doi: 10.1016/j.drugalcdep.2022.109696. Epub 2022 Nov 11.
2
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
Pulm Circ. 2019 Apr-Jun;9(2):2045894019848644. doi: 10.1177/2045894019848644.
3
Tailored combination prevention packages and PrEP for young key populations.
J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):19434. doi: 10.7448/IAS.18.2.19434. eCollection 2015.
4
New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.
Subst Abuse Rehabil. 2015 Jan 6;6:1-14. doi: 10.2147/SAR.S45585. eCollection 2015.
5
Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.
Am J Addict. 2014 Jan-Feb;23(1):34-40. doi: 10.1111/j.1521-0391.2013.12052.x. Epub 2013 Jun 10.
6
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.
Expert Rev Clin Pharmacol. 2013 May;6(3):249-69. doi: 10.1586/ecp.13.18.
7
Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.
Curr Infect Dis Rep. 2012 Feb;14(1):67-82. doi: 10.1007/s11908-011-0229-1.
8
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study.
Eur J Med Res. 2011 Oct 10;16(10):427-36. doi: 10.1186/2047-783x-16-10-427.
9
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.
Ther Drug Monit. 2011 Jun;33(3):309-14. doi: 10.1097/FTD.0b013e31821d3adb.
10
Gender differences in pharmacokinetics of maintenance dosed buprenorphine.
Drug Alcohol Depend. 2011 Nov 1;118(2-3):479-83. doi: 10.1016/j.drugalcdep.2011.03.024. Epub 2011 Apr 23.
本文引用的文献
1
Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.
Am J Drug Alcohol Abuse. 2009;35(2):68-72. doi: 10.1080/00952990802585406.
2
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
JAMA. 2008 Aug 6;300(5):555-70. doi: 10.1001/jama.300.5.555.
3
Review article: current antiviral therapy of chronic hepatitis B.
Aliment Pharmacol Ther. 2008 Jul;28(2):167-77. doi: 10.1111/j.1365-2036.2008.03731.x. Epub 2008 May 9.
4
Diagnosis and management of hepatitis B virus and HIV coinfection.
Top HIV Med. 2007 Nov-Dec;15(5):163-6.
5
Future prospectives for the management of chronic hepatitis B.
World J Gastroenterol. 2007 May 14;13(18):2554-67. doi: 10.3748/wjg.v13.i18.2554.
6
Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir.
Eur J Clin Microbiol Infect Dis. 2007 May;26(5):367-9. doi: 10.1007/s10096-007-0293-5.
7
Viral hepatitis in HIV infection.
N Engl J Med. 2007 Apr 5;356(14):1445-54. doi: 10.1056/NEJMra065142.
8
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.
Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S235-46. doi: 10.1086/508188.
9
Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.
Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S224-34. doi: 10.1086/508187.
10
Antiviral therapy of chronic hepatitis B.
Antiviral Res. 2006 Sep;71(2-3):206-15. doi: 10.1016/j.antiviral.2006.04.003. Epub 2006 Apr 25.
Zotero 插件